Erasca, Inc.
ERASHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeErasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. At a $6.65B market cap, Erasca, Inc. ranks as a mid-cap company within healthcare. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Market Cap
$6.65B
Beta
0.67
P/E (TTM)
—
P/E (Fwd)
-34.67
EPS (TTM)
$-0.94
EPS (Fwd)
$-0.55
ROE
-69.9%
ROA
-17.9%
Cash
$243.8M
Total Debt
$46.0M
Free CF
-$212.7M
52W Change
1178.0%
Annual Financials
Cash vs Debt
With $243.8M in cash and $46.0M in debt, ERAS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$212.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -69.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.67 suggests ERAS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Erasca, Inc.'s trajectory.